What was the most common adverse reaction to eladocagene exuparvovec in clinical studies of patients with AADC deficiency?

The most common adverse reaction to eladocagene exuparvovec in three open-label clinical studies involving 30 patients with AADC deficiency was dyskinesia, reported in 26 patients (86.7%) and prevalent during the first two months after treatment.